Skip to main content

Table 1 Demographic data and blood eosinophil counts of patients with GC-sensitive NP and GC-insensitive NP

From: Sinus computed tomography predicts clinical response to corticosteroids in chronic rhinosinusitis with nasal polyps

  Objective sensitivity Subjective sensitivity
GC-sensitive (n = 25) GC-insensitive (n = 22) P value GC-sensitive (n = 29) GC-insensitive (n = 18) P value
Male, NO. (%) 16 (64) 12 (54.5) .56 18 (62) 10 (55.6) .76
Age, mean (SD) (years) 39.5 (12.7) 34.8 (11.9) .21 40.4 (11.7) 32.4 (12.3) .03
Disease duration (years) 6.4 (8.4) 8.5 (9.0) .4 7.8 (10.1) 6.8 (6.0) .7
Smoking, NO. (%) 3 (12) 3 (13.6) > .99 5 (17.2) 1 (5.6) .38
Eosinophil count, mean (SD) (cells/μL) 404.4 (200.3) 209.5 (233.1) .003 401.4 (213.6) 171.1 (200.2) < .001
Eosinophil ratio, mean (SD) 5.25 (2.59) 3.17 (3.46) .02 5.39 (2.76) 2.48 (2.99) < .001
NPSS before treatment, mean (SD) 5.72 (1.37) 5.64 (1.29) .83 5.76 (1.38) 5.56 (1.25) .61
NPSS after treatment, mean (SD) 4.28 (1.46) 5.77 (1.31) < .001 4.55 (1.62) 5.67 (1.24) .02
TNSS before treatment, mean (SD) 8.8 (2.25) 8.05 (1.86) .22 9.07 (1.71) 7.44 (2.31) .01
TNSS after treatment, mean (SD) 6.5 (1.71) 7.59 (1.79) .04 6.53 (1.68) 7.78 (1.8) .02
Atopy, NO. (%) 17 (68) 13 (59.1) .45 21 (72.4) 9 (50) .16
Asthma, NO. (%) 11 (44) 3 (13.6) .02 12 (41.4) 2 (11.1) .03
AR, NO. (%) 11 (44) 7 (31.8) .4 14 (48.3) 4 (22.2) .12
AERD, NO. (%) 1 (4) 1 (4.5) .93 1 (3.4) 1 (5.6) .73
  1. GC, glucocorticoid; NPSS, nasal polyp size score; TNSS, total nasal symptom score; AR, allergic rhinitis; AERD, aspirin-exacerbated respiratory disease